Search Results

Norway Funds Research and Development of Microreactors for Marine Nuclear Propulsion

Recently, the Research Council of Norway announced an early-stage grant of US$2 million to the Marine Nuclear Power Systems (MarNuPS) project to support the integration and testing of maritime nuclear propulsion technology. It is reported that the project is led by the Norwegian subsidiary of Emerald Nuclear, a U.S. microreactor startup, with a total first-phase research budget of approximately US$15 million. Emerald's GEM microreactor concept uses tristructural isotropic (TRISO) high-assay low-enriched uranium fuel, has a refueling cycle of 5 to 15 years, and plans to adopt a "reactor leasing" rather than direct sales...

2026-10-28

Norway and Sweden Sign Long-Term Agreement for Cross-Border Processing of Spent Fuel from Decommissioned Research Reactors

Recently, the Norwegian Nuclear Decommissioning (NND) and the Swedish nuclear technical service provider Studsvik formally signed a landmark agreement in Halden valid until 2055, under which the latter will take full responsibility for the cross-border transport, inspection, oxidation treatment, and interim storage of spent nuclear fuel from the former research reactors at Halden and Kjeller in Norway. It is understood that Norway has accumulated approximately 16.5 tonnes of spent research reactor fuel over the past 60 years, including metallic uranium fuel, aluminum-clad fuel, and various experimental fuels, the vast majority of which cannot be directly subjected to long-term safe disposal. Under the agreement, Studsvik will transport this spent fuel to its licensed facility outside Nykoping, Sweden, for oxidation and other key processing, after which it will be temporarily stored in Sweden until it is returned to Norway in the future for final geological disposal.

2026-10-17

Thor Medical Advances AlphaOne Commercial Production in H1, Completes First Customer Deliveries of Lead-212 Isotope

Thor Medical ASA, a supplier of high-purity isotopes to the radiopharmaceutical industry, announced its H1 2026 results on August 28. The company stated that its AlphaOne facility has completed mechanical construction on time and on budget and has entered commercial production, marking the start of a new phase focused on scaling output, increasing customer deliveries, and growing revenue. Thor Medical CEO Jasper Kurth said that with the completion of the first customer product deliveries from AlphaOne, the company has established a solid commercial foundation in a rapidly growing market, and the next step is to advance the execution plan around capacity expansion, customer deliveries, and revenue growth to support the development of next-generation precision cancer therapies...

2026-08-28

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

Thor Medical Commences Commercial Supply with First Delivery of High-Purity Thorium-228 from AlphaOne

Thor Medical ASA announced on August 5 that it has completed the first customer delivery of high-purity thorium-228 (Th-228) from its AlphaOne production facility at the Herøya industrial park. This marks the first customer shipment following the facility's production start announced last week, and signifies AlphaOne's entry into the commercial supply phase. Thor Medical CEO Jasper Kurth stated that commercial production represents the beginning of the company's industrial-scale manufacturing, and the first customer delivery demonstrates the company's transition from capacity building to serving customers through its first industrial-scale facility. The company stated that as production capacity gradually ramps up, it will continue to meet the growing demand for high-purity isotopes in the targeted alpha therapy field...

2026-08-06

Thor Medical Launches Commercial Production of Lead-212 at AlphaOne Facility

Thor Medical ASA announced on July 31 that commercial production has commenced at its industrial-scale AlphaOne production facility located in the Herøya industrial park. The facility will produce lead-212 (Pb-212) and its precursors thorium-228 (Th-228) and radium-224 (Ra-224) to support demand related to radiopharmaceuticals and targeted cancer radiotherapy. According to the company, Thor Medical has signed supply agreements with multiple types of customers across the radiopharmaceutical value chain, including startup biotechnology companies, contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. The company expects the AlphaOne facility to deliver its first products to customers in August 2026. AlphaOn...

2026-08-01